Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Curtis E. Bemis who wrote (160)	10/4/1999 11:56:00 AM
From: LLCF	Respond to of 395

<Evidently, the demand for autism treatments has dried up the natural supply. Is that your understanding also ??> yes, people are ordering it from all over the world. DAK

To: Curtis E. Bemis who wrote (160)	10/4/1999 3:01:00 PM
From: LLCF	Read Replies (2) \| Respond to of 395

This is THE conference for Autism as far as I know. Secretin is part of the autism treatment called "The DAN Protecal": October 2, 1999 Cherry Hill, NJ. Dr. Walter Herlihy presented at the 5th Annual DAN Conference in Cherry Hill, NJ to more than 1000 medical professionals and parents working within the field of autism. Dr. Herlihy announced that RepliGen Corporation had acquired the rights to two in vivo diagnostic products based on the hormone secretin from ChiRhoClin, Inc. Secretin is a peptide hormone produced naturally by the body to stimulate the pancreas during the digestion of food. Secretin has been used for decades to test pancreatic function and to diagnose gastrinomia, and recently identified as a potential treatment for autistic children. Both diagnostic products are based on chemically synthesized forms of secretin; one based on porcine (pig) secretin, one based on human secretin. Synthetic versions of hormones such as secretin are preferred over the natural versions for their higher levels of purity and consistency, while remaining risk free from contamination by animal viruses. A New Drug Application (NDA) for diagnostic applications of synthetic porcine secretin was filed with the FDA (Food and Drug Administration) in May 1999 and is currently under review. An New Drug Application for synthetic human secretin is expected to be filed in early 2000. The FDA typically takes 6 to 18 months to review a New Drug Application and, if appropriate, to grant approval for market distribution. Dr. Herlihy also announced the sites for a double-blind placebo-controlled clinical trial. The study will take place at three locations: University of Maryland Medical Center, The Mayo Clinic in Rochester, Minnesota, and The Royal Free Hospital in London beginning in January 2000. If you would like more information on our clinical trials, please visit our website at www.secretin-repligen.com. Please do not contact the clinical trial sites; they are not prepared to answer calls at this time. We will forward all requests to the sites when they are ready to process the information. For any further information on secretin biology, GI issues and autism, or to learn about the progress of secretin research, please visit our website www.secretin-repligen.com DAK